Scarica l'app Stockscreener
3.626
9.51%
0.366
Precedente Chiudi:
$3.26
Aprire:
$3.19
Volume 24 ore:
20,010
Relative Volume:
0.43
Capitalizzazione di mercato:
$4.39M
Reddito:
-
Utile/perdita netta:
$-13.52M
Rapporto P/E:
-4.90
EPS:
-0.74
Flusso di cassa netto:
$-10.03M
1 W Prestazione:
-6.54%
1M Prestazione:
+2.81%
6M Prestazione:
-87.56%
1 anno Prestazione:
-75.19%
Intervallo 1D:
$3.19
$3.80
Intervallo di 1 settimana:
$3.05
$3.975
Portata 52W:
$2.86
$79.00
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
Nome
Kazia Therapeutics Limited Adr
Settore
Industria
Telefono
01161298780088
Indirizzo
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Confronta KZIA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
3.63 | 4.39M | 0 | -13.52M | -10.03M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.89 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
539.24 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
548.06 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.01 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
230.82 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Iniziato | Maxim Group | Buy |
| 2021-10-14 | Iniziato | Maxim Group | Buy |
| 2021-01-05 | Iniziato | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr Borsa (KZIA) Ultime notizie
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE - marketscreener.com
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS - marketscreener.com
Kazia announces voluntary delisting from ASX - marketscreener.com
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA - marketscreener.com
GBM AGILE OPENS TO PAXALISIB IN EUROPE - MarketScreener
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY - marketscreener.com
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING - marketscreener.com
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium - marketscreener.com
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO - marketscreener.com
SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow
Kazia Therapeutics-Plans To Change Ratio Of Its Adss To Ordinary Shares To One ADS Representing 500 Ordinary Shares - marketscreener.com
Kazia Therapeutics sells Cantrixil rights for $1 million - Investing.com India
Kazia's Million-Dollar Deal: Cantrixil Cancer Drug IP Rights Sold as Development Path Shifts - Stock Titan
Kazia Therapeutics shares annual report details By Investing.com - Investing.com South Africa
Kazia Therapeutics shares annual report details - Investing.com
Best upcoming stock splits and reverse splits 2024 - Investorsobserver
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease - BioSpace
Kazia explores paxalisib for Parkinson's with MJFF grant - Investing.com
Kazia Therapeutics Awarded Research Grant to Explore Paxalisib’s Potential for Parkinson’s Treatment - TipRanks
KZIA’s Stock Journey: What Investors Need to Know About Kazia Therapeutics Limited ADR’s Performance - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) Stock: Analyzing the Market Value - The News Heater
SolarBank Corporation (SUUN) Stock: Evaluating the Market Performance - The News Heater
Aditxt Inc (ADTX) Stock: A Look at the Analyst Recommendations - The News Heater
Maxim Group Begins Coverage on Kazia Therapeutics (NASDAQ:KZIA) - Defense World
10 Best ASX Stocks to Buy According to Hedge Funds - Insider Monkey
Game-Changing Cancer Trial: Kazia's New Drug Combo Could Unmask Hidden Breast Cancer Cells - StockTitan
Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now? - Insider Monkey
10 Best Australian Stocks to Buy Now - Insider Monkey
Kazia Therapeutics Secures $2M Funding Through Direct Offering to Alumni Capital - StockTitan
Kazia Therapeutics secures $2 million in direct offering - Investing.com India
Kazia Therapeutics Secures $2M Funding Through Direct Offering at $1.50 Per ADS - StockTitan
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Yahoo Finance
Kazia aligns with FDA on glioblastoma drug study design - Investing.com India
Kazia's Brain Cancer Drug Paxalisib Shows 3.8-Month Survival Benefit, FDA Guides Phase 3 Path Forward - StockTitan
Kazia Therapeutics Shares Fall After FDA Declines Accelerated Drug Approval - marketscreener.com
Kazia's Paxalisib Shows Promise in Breast Cancer Trial: Key Data Released at SABCS - StockTitan
Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - Mitrade
Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq
Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing - Yahoo Finance
B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Immunotherapy Clinical TrialsA New Approach to Treating Cancer - StockTitan
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER - marketscreener.com
7 Top Stocks Under $10: July 2024 Edition - InvestorPlace
United States shares higher at close of trade; Dow Jones Industrial Average up 0.53% - Investing.com India
United States shares higher at close of trade; Dow Jones Industrial Average up 0.62% - Investing.com India
Kazia Therapeutics Limited Adr Azioni (KZIA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.11%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):